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Aims: To determine the threshold intrahepatic lipid (IHL) content separating metabolically
normal from abnormal in a Japanese population based on protonmagnetic resonance spec-
troscopy (1H-MRS).
Methods: A total of 305 Japanese subjects aged 20–69 years were investigated. The subjects
underwent general examination, blood tests, and 1H-MRS of the liver after an overnight
fast. They completed a questionnaire about daily drinking habits and their daily alcohol
intake was calculated.
Results: The median IHL content was 4.7% in men and 1.7% in women, and it increased
along with the number of features of metabolic syndrome (MetS). The optimum IHL cut-
off value for separating normal subjects from those with at least one feature of MetS
was 6.5% in men (AUC of ROC: 0.727, 95%-CI: 0.649–0.804) and 1.8% in women (0.765,
0.685–0.844). Alcohol intake was not correlated with the IHL content according to multiple
logistic regression analysis.
Conclusion: This study demonstrated a close association of IHL with features of MetS and
identified IHL content cut-off values for metabolic normality in Japanese subjects.
 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Metabolic syndrome (MetS) is a cluster of risk factors (visceral
obesity, hyperglycemia, dyslipidemia, and hypertension) that
is considered to promote the development of type 2 diabetes
mellitus (T2DM) and cardiovascular disease (CVD) [1]. It hasbeen reported that persons with MetS have a fivefold and
threefold increased risk of developing T2DM and CVD, respec-
tively [2]. In addition, Klein et al. estimated that persons with
four or more features of MetS are approximately 35 times
more likely to develop T2DM than persons without any
features [3]. The features of MetS include visceral fatity School
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sion. Among them, visceral fat accumulation is fundamental
to MetS and precedes the others, because excess visceral fat
with enlarged adipocytes and infiltratingmacrophages causes
insulin resistance that induces other features of MetS by dis-
rupting the balance of adipokines and chemokines [4,5].
Recently, excessive accumulation of intrahepatic lipid
(IHL), generally known as fatty liver, has also been reported
to cause insulin resistance [6–10], although it is not included
among the features of MetS. In fact, some reports have sug-
gested that the association of excess IHL with indices of insu-
lin resistance may be stronger than that of excess visceral fat
[11,12]. We previously reported that the IHL content measured
by proton magnetic resonance spectroscopy (1H-MRS), but not
the visceral fat volume measured by whole-abdominal com-
puted tomography (CT) scanning (700–800 slices), was signifi-
cantly correlatedwith two indices of insulin resistance, which
were Homeostasis Model Assessment of Insulin Resistance
(HOMA-IR) and the Matsuda Index [13]. While the mechanism
by which excess IHL causes insulin resistance has not been
fully elucidated, it has been suggested that some intracellular
metabolites of triglycerides, such as ceramide or diacylglyc-
erol, may interfere with intracellular insulin signaling in the
liver [14,15]. Additionally, there have been reports that the
hepatokine fetuin-A, production of which is increased in fatty
liver, induces insulin resistance and subclinical inflammation
in mice and humans [16–18]. These previous reports have
indicated that measurement of IHL is important for assessing
MetS.
1H-MRS focusing on segment 6 of the liver has been used
as a noninvasive method for quantitative measurement of
the IHL content. Recent 1H-MRS studies have also demon-
strated that the 95th percentile of IHL is 5.6% and 3.0% in a
low-risk mixed population (Hispanic, Caucasian, and African
American) [19] and a lean Caucasian population [20], respec-
tively. The median IHL content has also been reported for sev-
eral ethnic groups other than Japanese [19,21,22]. However,
there have been no reports about IHL values in metabolically
normal persons. Accordingly, the cut-off value for a Japanese
population that separatesmetabolically normal personswith-
out any features of MetS from persons with at least one fea-
ture of MetS has not been determined. Thus, the aim of this
study was to identify the IHL thresholds separating metabol-
ically normal persons from metabolically abnormal persons
in a Japanese population by using 1H-MRS for measurement
of hepatic lipid.
2. Materials and methods
2.1. Subjects
A total of 318 consecutive Japanese subjects aged 20–
69 years undergoing general health screening at the Interna-
tional University of Health and Welfare Hospital (IUHW)
were recruited for this study during the period from April
2014 to March 2015. We excluded persons with a history of
treatment with medications for diabetes, dyslipidemia, or
hypertension, alcohol abuse (alcohol intake >60 g/day) [23],
liver disease (hepatitis B or C, autoimmune hepatitis, etc.),atherosclerotic disease (stroke, coronary heart disease, or
peripheral vascular disease), or chronic kidney disease, as
well as pregnant or breast-feeding women. After measure-
ment of the height, body weight, waist circumference, and
blood pressure, blood tests and 1H-MRS of the liver were
performed in the morning after an overnight fast. Drinking
habits were assessed using a questionnaire (Table 1), and
daily alcohol intake was calculated as follows: alcohol
intake at one session (g)  frequency of drinking alcohol
(days per week or month)/7 (days) or 28 (days). We divided
the subjects into three groups, which were non-drinkers,
light drinkers (<20 g/day for men and <10 g/day for women),
and moderate drinkers (=20 g/day for men and =10 g/day for
women) [24]. The present study was conducted according to
the principles of the Declaration of Helsinki and was
approved by the institutional ethics committee of IUHW
(registration number: 13-B-48). Informed consent was
obtained from all of the subjects.
2.2. Measurements
Height and body weight were measured by an automated
device (BF-220, Tanita Co. Ltd., Japan). Waist circumference
was measured at the umbilicus in a standing position during
quiet breathing by using a nonstretchable tape measure. In
subjects with marked periumbilical fat accumulation, mea-
surement was done at a point midway between the lower
margin of the ribs and the anterior superior iliac spine. Blood
pressure was measured in the sitting position by using one of
two automatic devices (UA-786, A&D Co. Ltd., Japan, Kentaro
HBP-9020, Omron Co. Ltd., Japan).
2.3. Laboratory tests
A blood sample was collected in the morning while fasting.
Free fatty acids (FFA) and insulin were measured by an enzy-
matic method (LSI Medience Co. Ltd., Tokyo, Japan) and a
chemiluminescence immunoassay (LSI Medience Co. Ltd.),
respectively. Glycohemoglobin (HbA1c) was measured by the
latex agglutination method, and other blood tests were per-
formed by standard methods (SRL Co. Ltd., Tokyo, Japan).
The homeostasis model assessment of insulin resistance
(HOMA-R) and HOMA of b-cell function (HOMA-b) were calcu-
lated as reported previously [25].
2.4. Evaluation of MetS
To evaluate MetS, the following five criteria recommended
for Asian populations by the Joint Scientific Statement [26]
were used: (1) waist circumference (WC) P90 cm in men
and P80 cm in women, (2) fasting serum triglyceride (TG)
level P150 mg/dL, (3) fasting serum HDL-cholesterol (HDL-
C) level <40 mg/dL in men and <50 mg/dL in women, (4) sys-
tolic blood pressure (SBP) P130 mmHg and/or diastolic blood
pressure (DBP) P85 mmHg, and (5) fasting plasma glucose
(FPG) level P100 mg/dL. Subjects with none of these criteria
were defined as metabolically normal, while those with
three or more of the above criteria were classified as having
MetS.
Table 1 – Questionnaire about drinking alcohol.
Question 1. How often do you usually have any kind of drink containing alcohol?
 every day
 not every day, but ___ day(s) per week
 not every week, but ___ day(s) per month
 never or don’t drink at all
Question 2. For drinkers. What kind of alcohol do you drink? (multiple answers allowed)
 Japanese sake
 beer
 shochu
 whiskey, brandy
 wine
 chuhai in cans
 others
Question 3. For drinkers. When drinking, how many drinks do you usually have? One
drink refers to 180 ml of sake, one beer (500 mL), 80 mL of shochu, 60 mL of whiskey, 2 glasses of
wine (240 mL), or a can of chuhai (520 mL).
 less than one drink
 between 1 and 2 drinks
 between 2 and 3 drinks
 3 drinks or more
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The IHL content was measured by 1H-MRS in the morning
after an overnight fast, as described previously [13,27,28].
Briefly, spectroscopic images of the liver were acquired with
a 1.5 T whole body system (Intera Achieva; Philips Medical
Systems, Eindhoven, Netherlands) using a Sense Flex M coil
(Philips Medical Systems). The voxel (20  20  20 mm3) was
centered on segment 6 of the liver while taking care to avoid
major blood vessels, intrahepatic bile ducts, and the lateral
border of the liver. Subjects remained in the supine position
with normal respiration during measurement. Spectra were
acquired using a point-resolved spectroscopy sequence
(PRESS) with a repetition time of 2000 ms, echo time of
144 ms, acquisition number of 128, and 512 data points over
a 1000 Hz spectral width. Then IHL was quantified from the
methylene proton peaks (-CH2) of fatty acids at 1.3 parts/ mil-
lion (ppm). Spectrum fitting and analysis were done with LC
Model software (version 6.3–1 J; Provencher, PhD, Oakvile,
Ontario, Canada). The IHL content was calculated as follows:
[area under the curve of the methylene proton peak (AUC-
IHL)/AUC-IHL + area under the water proton peak (AUC-
H2O)]  100.
2.6. Statistical analysis
All statistical analyses were performed with EZR (Saitama
Medical Center, Jichi Medical University, Saitama, Japan) and
the graphical user interface for R (The R Foundation for Statis-
tical Computing, Vienna, Austria), which is a modified version
of R commander with statistical functions frequently
employed in biostatistics. Continuous variables were
expressed as the mean ± SD and were compared using the
unpaired t-test if the distribution was normal. Skewed vari-
ables were expressed as median values (interquartile range
(IQR)) and were compared by the Mann–Whitney U-test and
Kruskal–Wallis test. Correlations between variables were
determined by using Spearman’s rank test. Q–Q plots wereemployed to screen variables for a normal distribution. Recei-
ver operating characteristic (ROC) curves were plotted for the
IHL content predicting the presence of one or more risk fac-
tors for themetabolic syndrome, as defined by the Joint Scien-
tific Statement. The sensitivity and specificity were calculated
for the threshold values that maximized the Youden index.
We performed multiple regression analysis to clarify the
effect of alcohol on the IHL in the present study to the exclu-
sion of IRI, HOMA-R, HOMA-b and the MetS risk factors such
as HDL, FPG, TG, SBP and WC from independent variables on
the assumption that accumulation of IHL leads to hepatic
insulin resistance and is one of fundamental to MetS. There
was low collinearity between body mass index (BMI) and
ALT (r = 0.435), FFA (r = 0.005) in Spearman rank test. Finally,
Age, gender, FFA, alanine aminotransferase (ALT), BMI and
alcohol intake were selected as independent variables. When
data were skewed, logarithmic transformation was per-
formed before multiple regression analysis. Statistical signif-
icance was defined as a p value less than 0.05.
2.7. Missing data
Subjects without missing date were used in each analysis.
The number of missing items for each variable is shown in
the tables.
3. Results
Supplementary Fig. 1 displays a flowchart of participant selec-
tion. Eight subjects were excluded due to a history of medica-
tions for diabetes, dyslipidemia, or hypertension and five
subjects were excluded because they had a history of liver dis-
ease. The remaining 305 subjects underwent body measure-
ments, laboratory tests, and 1H-MRS. Clinical characteristics
of the 305 subjects are summarized in Table 2. The mean
age and median BMI were 48 ± 10 years and 21.7 kg/m2,
respectively. The median IHL content was 2.6% (4.7% in men
and 1.7% in women). When men and women were compared,
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aminotransferase (AST), ALT, c-Glutamyltranspeptidase (c-
GTP), daily alcohol intake, and IHL were all higher in men
than women, while, HDL-C was lower in men than in women.
On the other hand, the age, total cholesterol (T-CHO), LDL-C,
HbA1c, fasting plasma insulin (FPI), FFA, HOMA-IR, and
HOMA-b did not differ between men and women. If an IHL
content of 5.5% is accepted as defining hepatic steatosis
[19], 32% of the 305 subjects had hepatic steatosis, including
44% of the men and 19% of the women.
The distribution of the IHL content classified by the num-
ber of MetS features is shown in Fig. 1, with levels ranging
from 0 to 64.4%. The IHL content distribution was positively
skewed with a tail extending to higher values. The 5th, 25th,
75th, 95th percentiles were 0.4, 1.5, 11.3, and 36.6% in men,
respectively, and 0.1, 0.6, 3.9, and 13.3% in women, respec-
tively. Subjects of both genders with three or more MetS fea-
tures (MetS group) generally had an IHL content higher than
30.0%. The IHL content distribution was skewed more
strongly toward low values in women than in men.
Table 3 shows the values of IHL classified by the number of
MetS features. The metabolically normal subjects (normal
group) included 76 men (47.8%) and 85 women (58.2%), while
the subjects with three or more MetS features (MetS group)
included 17 men (10.7%) and 12 women (8.2%). The subjects
who were neither normal nor MetS (intermediate group)
included 66 men (41.5%) and 49 women (33.6%). The median
IHL content of the normal group, intermediate group, and
MetS group was respectively 2.7%, 6.0%, and 36.2% for men,
while it was respectively 0.8%, 2.5%, and 11.2% for women.
Median IHL increased significantly along with the number of
MetS features in both men and women. The clinical charac-
teristics classified by the number of MetS features were
shown in Supplementary Tables 1 and 2.Table 2 – Baseline clinical characteristics of the subjects. Contin
[interquartile range(IQR)]. *NA: the number not assessed. ap value
test.
Clinical characteristics All subjects
n 305
Age, yr 48 ± 10
Body mass index, kg/m2 21.7 [20.2, 23.4]
Waist circumference, cm 79.5 ± 9.0
Systolic blood pressure, mmHg 117 ± 14
Diastolic blood pressure, mmHg 74 ± 11
Total cholesterol, mg/dL 200 ± 33
Triglycerides, mg/dL 81 [60, 116]
HDL cholesterol, mg/dL 62 ± 15
LDL cholesterol, mg/dL 119 ± 29
Fasting plasma glucose, mg/dL 89 [83, 96]
Hemoglobin A1c, % (NA*) 5.5 [5.2, 5.7](13)
Hemoglobin A1c, mmol/mol (NA) 36 [33, 38](13)
Fasting plasma insulin, lU/mL (NA) 4.2 [3.0, 5.7](4)
Free fatty acid, mEq/L (NA) 0.4 ± 0.1(84)
Aspartate aminotransferase, IU/L (NA) 22 [18, 25](12)
Alanine aminotransferase, IU/L (NA) 18 [13, 25](11)
c- glutamyl transpeptidase, IU/L (NA) 22 [15, 37](11)
HOMA-R (NA) 0.9 [0.6, 1.3](4)
HOMA-b (NA) 60.0 [42.2, 79.4](4)
Alcoholic intake, g (NA) 11.6 ± 16.7(29)
Intrahepatic lipid content, % 2.6 [0.9, 8.1]Fig. 2 displays receiver operating characteristic (ROC)
curves identifying the IHL cut-off values for men and women
that provided optimal separation between subjects with no
features of MetS and subjects with at least one feature of
MetS. According to ROC analysis, the IHL cut-off values with
the maximum sensitivity and specificity were 6.5% for men
and 1.8% for women. The sensitivity and specificity of the
cut-off value was respectively 60.2% and 77.6% in men and
78.7% and 70.6% in women. The area under the ROC curve
(AUC) was 0.727 [95% CI 0.649–0.804] in men and 0.765
[0.685–0.844] in women. In addition, the IHL cut-off value sep-
arating subjects with or without MetS was 9.5% for men and
5.0% for women. The sensitivity and specificity of the cut-
off value was respectively 100% and 73.9% in men and 91.7%
and 85.8% in women, while the AUC of the ROC curve was
0.916 [95% CI 0.860–0.972] in men and 0.925 [0.865–0.984] in
women.
We also evaluated the influence of alcohol intake. There
was no correlation between the IHL content and alcohol
intake (g/day) when this was assessed in all subjects
(r = 0.05, p = 0.36). Then we divided the subjects into three
groups based on alcohol consumption. The median IHL con-
tent of non-drinkers, light drinkers, and moderate drinkers
was respectively 6.4%, 3.4%, and 5.1% for men, while it was
respectively 1.9%, 1.8%, and 0.6% for women. There were no
significant differences among these groups (p = 0.08 in men
and p = 0.20 in women). Ultimately, multiple logistic regres-
sion analysis revealed that age, log-ALT and log-BMI were cor-
related with log-IHL, but gender, FFA and alcohol intake were
not (Table 4). There was low collinearity between BMI and ALT
(r = 0.435), FFA (r = 0.005) according to Spearman’s rank test.
Finally, Age, gender, FFA, alanine aminotransferase (ALT),
BMI and alcohol intake were selected as independent
variables.uous variables are expressed as the mean ± SD or median
swere calculated by unpaired t test or the Mann–Whitney U-
Men Women p valuea
159 146
48 ± 10 48 ± 11 0.417
22.7 [21.1, 24.3] 20.8 [19.0, 22.0] 0.000
82.7 ± 8.8 75.9 ± 7.8 0.000
120 ± 13 113 ± 15 0.000
76 ± 10 71 ± 12 0.000
197 ± 32 204 ± 35 0.051
91 [72, 130] 70 [54, 78] 0.000
57 ± 14 68 ± 15 0.000
119 ± 28 118 ± 29 0.901
91 [85, 99] 87 [83, 94] 0.000
5.5 [5.2, 5.7](7) 5.5 [5.2, 5.8](6) 0.093
36 [33, 38](7) 36 [33, 39](6) 0.093
4.2 [2.9, 6.0](3) 4.2 [3.2, 5.5](1) 0.696
0.4 ± 0.1(50) 0.5 ± 0.1(34) 0.07
23 [19, 27](6) 19 [17, 22](6) 0.000
22 [17, 28](5) 15 [13, 19](6) 0.000
31 [19, 51](5) 16 [12, 22](6) 0.000
0.9 [0.7, 1.4](3) 0.9 [0.6, 1.2](1) 0.354
56.9 [37.5, 78.6](3) 62.7 [47.4, 79.6](1) 0.131
16.6 ± 18.2(14) 6.2 ± 12.9(15) 0.000
4.7 [1.5, 11.3] 1.7 [0.6, 3.9] 0.000
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There were four main findings of the present study. First, the
median IHL content was 2.6% in Japanese subjects undergo-
ing health screening (4.7% in men and 1.7% in women). Sec-
ond, the IHL content increased along with an increase in
the number of features of MetS. Third, the cut-off value of
the IHL content for metabolic normality was 6.5% in Japanese
men and 1.8% in Japanese women. Fourth, alcohol intake was
not correlated with the IHL content.
Previous studies have shown that the median IHL content
of the general population was 4.6% in 401 Hispanics, 3.6% in
734 Caucasians, 3.2% in 1105 Blacks [21], and 2.1% in 922 Hong
Kong Chinese [22]. The present study demonstrated that the
median IHL content was 2.6% in 305 Japanese adults, while
the mean IHL content was reported to 9.6 ± 1.0 mmol/L in 69
Japanese patients with NAFLD [29]. Szczepaniak et al. previ-
ously reported that the 95th percentile of the IHL content
was 5.6% in a population of 160 men and 185 women (140
Blacks, 143 Caucasians, 51 Hispanics, and 11 others) whowere
considered to have a low risk of hepatic steatosis (BMI <25 kg/
m2, low alcohol consumption, normal FPG, normal ALT, and
non-diabetes) [19]. This value has been used to distinguishIntrahepac
(%)
(A)
Intrahepa
(%)
(B)
Fig. 1 – Distribution of the intrahepatic lipidbetween subjects with or without hepatic steatosis in several
previous reports [21,22,30], because of concordance with an
earlier study in which hepatic tissue triglyceride levels were
measured at autopsy [31]. The percentage of subjects with
hepatic steatosis was 32% in the present study, which was
equivalent to the percentage in previous reports (33.6% in
the Dallas County population [19] and 29% in Hong Kong Chi-
nese [22]).
Our study demonstrated that the median IHL content
increased significantly along with the number of MetS fea-
tures in both men and women (Table 3). While IHL is not
included among the features of MetS, previous studies have
suggested that abnormal accumulation of IHL is more
strongly associated with insulin resistance than visceral fat
volume [11,12]. In these studies, insulin sensitivity was mea-
sured by the hyperinsulinemic euglycemic clampmethod, but
we used HOMA-IR and the Matsuda Index obtained from the
oral glucose tolerance test as indices of insulin sensitivity in
the present study. We previously found that the IHL content
was correlated with both HOMA-IR and the Matsuda Index
in obese Japanese obese subjects [13], while there were no cor-
relations with total visceral fat volume assessed by our origi-
nal method of analyzing 700–800 slices obtained by full lipid content (%)
Number of risk factors
c lipid content (%)
Number of risk factors
(IHL) content in men (A) and women (B).
Table 3 – Number of risk factors for metabolic syndrome. Significant differences of the IHL content were noted among groups
stratified by the number of risk factors for metabolic syndrome (p < 0.01 in men and women, Kruskal–Wallis test). *p < 0.05
was calculated by using Steel–Dwass test between normal and 1–2 risk or MetS group. †p < 0.05 was calculated by using Steel–
Dwass test between 1–2 risk and MetS group.
Number of risk factors All subjects Men Women
IHL, %/n (%)
0 (normal) 1.5 [0.6,3.7]/161 (52.8) 2.7 [1.0,5.7]/76 (47.8) 0.8 [0.4,2.0]/85 (58.2)
1–2 3.9 [1.8,9.6]*/115 (37.7) 6.0 [2.1,13.7]*/66 (41.5) 2.5 [1.6,4.6]*/49 (33.6)
3–5 (MetS) 22.4 [10.9,45.9]*†/29 (9.5) 36.2 [13.3,49.8]*†/17 (10.7) 11.2 [6.2,32.7]*†/12 (8.2)
Specificity
Se
ns
iti
vi
ty
0.0
0.2
0.4
0.6
0.8
1.0
1.0 0.8 0.6 0.4 0.2 0.0
6.540 (0.776, 0.602)
1.770 (0.706, 0.787)
men 
women
Fig. 2 – Receiver operating characteristic (ROC) curves for the
intrahepatic lipid (IHL) content predicting the presence of
risk factors for metabolic syndrome in men and women. d,
cut-off IHL content yielding the maximum sensitivity
+ specificity for predicting risk factors for metabolic
syndrome.
Table 4 – Multiple regression analysis of the relations
between the log-transformed intrahepatic lipid (IHL) content
and clinical parameters/characteristics.
b p value
Gender 7.4108 0.000
Age 2.2851 0.023
FFA 1.4823 0.139
Log (ALT) 5.3381 0.000
Log (BMI) 6.6068 0.000
Alcohol intake (g/day) 0.5006 6.171
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dietary intake of glucose and FFA derived from lipolysis of vis-
ceral fat via the portal vein, with excess food intake and low
energy consumption being major causes of fatty liver and vis-
ceral obesity [14]. Accordingly, IHL and visceral fat are proba-
bly not independent and are likely to influence each other,
and the IHL content was actually shown to be correlated with
WC inmen andwomen in the present study (date not shown).
While obesity is associated with metabolic abnormalities,
about 30% of obese subjects with a high BMI do not have
detectable metabolic abnormalities [33]. This state is called
metabolically healthy obesity (MHO), and persons with MHO
tend to have relatively less IHL and visceral fat despite their
excessive subcutaneous fat [34,35]. It was recently reported
that MHO subjects show increased lipogenesis in their subcu-
taneous adipose tissue, which may protect them from ectopic
fat accumulation at sites such as IHL [36]. Therefore, assess-
ment of both IHL and visceral fat mass regardless of BMI
may be important for evaluation of MetS or the response of
MetS to intervention. However, the IHL content for completelymetabolic normal persons without any features of MetS has
not been determined by the research performed to date.
Reference values of the 95th percentile of the IHL content
have been reported in low-risk groups for hepatic steatosis
[19,20], and the cut-off IHL content for hepatic steatosis was
found to be accurate for this purpose in an Asian population
by comparison with liver biopsy data [37]. However, there
have been no reports about the cut-off IHL content for defin-
ing metabolically normal persons. The present study is the
first to propose cut-off values for the IHL content based on
ROC analysis, which demonstrated moderate sensitivity and
specificity of our proposed values for men and women. While
liver biopsy is reasonable in a population study, but was not
performed in the present study, the results are virtually inter-
changeable with these two MR-based techniques (MRS and
MRI) for measuring the proton density fat fraction. Compar-
ison between MR-based fat fraction thresholds and histologi-
cal steatosis has been defined and validated in two studies
[38,39]. Interestingly, the 6.5% threshold to separate metabol-
ically normal from abnormal in men based on features of
metabolic syndrome in the present report is very close to
the 6.4% threshold for separating no steatosis from steatosis
based on histopathological examination [38].
Excessive alcohol consumption leads to alcoholic liver
disease, which progresses from simple steatosis to steato-
hepatitis, fibrosis, cirrhosis, and even hepatocellular carci-
noma, with such changes possibly being mediated by
ethanol-related oxidative stress, abnormal intracellular
metabolites, malnutrition, or endotoxins [40]. However, the
details of the influence of ethanol on fatty liver are still
unclear. Gunji et al. reported an inverse association between
alcohol intake and fatty liver in a large population of
Japanese subjects [41]. They found that the prevalence of
fatty liver among 5599 asymptomatic Japanese men was
significantly lower for those with light (40–140 g/week) or
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their study used only ultrasonography to detect fatty liver
and no other imaging studies or biomarkers were employed.
In the Hong Kong study, there was only a weak correlation
between the IHL content and alcohol consumption, and
the effect was even smaller after adjustment for other meta-
bolic factors [22]. In the present study, alcohol intake did not
show a correlation with the IHL content and was unrelated
to IHL according to multiple logistic regression analysis. A
recent animal study showed that hepatic aldehyde dehydro-
genase 2 (ALDH2) deficient ameliorates alcoholic fatty liver,
but worsens hepatic inflammation and fibrosis [42]. In East
Asia, up to 50% of the population may carry the ALDH2*2
allele [43], which has much lower activity than the wild-
type allele (ALDH2*1), and may thus have a preventive effect
on accumulation of IHL. Although we did not perform
ALDH2 gene analysis, the ALDH2 genotype may have influ-
enced our results. It needs to take account of individual
specificity about ethanol metabolism in order to evaluate
the effect of ethanol for fatty liver.
The present study had several limitations. First, the study
population was not so large and the subjects were nearly all
from Tochigi prefecture (located about 100 km north of
Tokyo). Thus, the subjects might not represent the general
Japanese population. Second, alcohol intake was assessed
from a self-reported questionnaire, which may possibly have
resulted in underestimation, and the accuracy of our alcohol
data is debatable [44]. Third, the separate threshold found
for women (1.8%) was very low. It is concerning that this is
below the actual precision of MR techniques, which showed
a coefficient of variation of 8.5% in the reproducibility arm
of the Dallas Heart Study [19]. Such a low threshold below
the noise floor of MR techniques may lead to overdiagnosis
if this method is used elsewhere without validation with
histopathology. Fourth, the 1H-MRS technique used in this
study only quantitated the methylene (CH2) peak of triglyc-
erides, which may represent as little as 60% (worst-case sce-
nario) of the fat content in patients with severe steatosis
[45]. Finally, it was difficult to compare exactly our MRS data
with results from other studies because the MRI unit, coil,
and sequence protocols vary among institutions.5. Conclusions
Based on the present results, we propose that the cut-off
value of the IHL content should be 6.5% in Japanese men
and 1.8% in Japanese women for separating metabolically
normal persons from those with at least one risk factor for
MetS. These values could be useful for researchers, who can
calculate changes of IHL and also assess whether their sub-
jects are metabolically normal or not. Further studies of larger
populations recruited nationwide will be need to confirm the
present findings.Disclosure
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